Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Passive Aβ Immunotherapy: Current Achievements and Future Perspectives.

Schilling S, Rahfeld JU, Lues I, Lemere CA.

Molecules. 2018 May 3;23(5). pii: E1068. doi: 10.3390/molecules23051068. Review.

2.

Deposition of phosphorylated amyloid-β in brains of aged nonhuman primates and canines.

Kumar S, Frost JL, Cotman CW, Head E, Palmour R, Lemere CA, Walter J.

Brain Pathol. 2018 May;28(3):427-430. doi: 10.1111/bpa.12573. No abstract available.

PMID:
29740941
3.

Age-related epigenetic changes in hippocampal subregions of four animal models of Alzheimer's disease.

Lardenoije R, van den Hove DLA, Havermans M, van Casteren A, Le KX, Palmour R, Lemere CA, Rutten BPF.

Mol Cell Neurosci. 2018 Jan;86:1-15. doi: 10.1016/j.mcn.2017.11.002. Epub 2017 Nov 4.

PMID:
29113959
4.

Complement C3 deficiency protects against neurodegeneration in aged plaque-rich APP/PS1 mice.

Shi Q, Chowdhury S, Ma R, Le KX, Hong S, Caldarone BJ, Stevens B, Lemere CA.

Sci Transl Med. 2017 May 31;9(392). pii: eaaf6295. doi: 10.1126/scitranslmed.aaf6295.

PMID:
28566429
5.

mTORC2 (Rictor) in Alzheimer's Disease and Reversal of Amyloid-β Expression-Induced Insulin Resistance and Toxicity in Rat Primary Cortical Neurons.

Lee HK, Kwon B, Lemere CA, de la Monte S, Itamura K, Ha AY, Querfurth HW.

J Alzheimers Dis. 2017;56(3):1015-1036. doi: 10.3233/JAD-161029.

6.

Antibody Engineering & Therapeutics 2016: The Antibody Society's annual meeting, December 11-15, 2016, San Diego, CA.

Larrick JW, Alfenito MR, Scott JK, Parren PW, Burton DR, Bradbury AR, Lemere CA, Messer A, Huston JS, Carter PJ, Veldman T, Chester KA, Schuurman J, Adams GP, Reichert JM.

MAbs. 2016 Nov/Dec;8(8):1425-1434. Epub 2016 Aug 24.

7.

Immunotherapy targeting pyroglutamate-3 Aβ: prospects and challenges.

Cynis H, Frost JL, Crehan H, Lemere CA.

Mol Neurodegener. 2016 Jun 30;11(1):48. doi: 10.1186/s13024-016-0115-2. Review.

8.

Complement and microglia mediate early synapse loss in Alzheimer mouse models.

Hong S, Beja-Glasser VF, Nfonoyim BM, Frouin A, Li S, Ramakrishnan S, Merry KM, Shi Q, Rosenthal A, Barres BA, Lemere CA, Selkoe DJ, Stevens B.

Science. 2016 May 6;352(6286):712-716. doi: 10.1126/science.aad8373. Epub 2016 Mar 31.

9.

Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Head E, Lott IT, Wilcock DM, Lemere CA.

Curr Alzheimer Res. 2016;13(1):18-29. Review.

10.

In Vivo Detection of Age- and Disease-Related Increases in Neuroinflammation by 18F-GE180 TSPO MicroPET Imaging in Wild-Type and Alzheimer's Transgenic Mice.

Liu B, Le KX, Park MA, Wang S, Belanger AP, Dubey S, Frost JL, Holton P, Reiser V, Jones PA, Trigg W, Di Carli MF, Lemere CA.

J Neurosci. 2015 Nov 25;35(47):15716-30. doi: 10.1523/JNEUROSCI.0996-15.2015.

11.

An anti-pyroglutamate-3 Aβ vaccine reduces plaques and improves cognition in APPswe/PS1ΔE9 mice.

Frost JL, Liu B, Rahfeld JU, Kleinschmidt M, O'Nuallain B, Le KX, Lues I, Caldarone BJ, Schilling S, Demuth HU, Lemere CA.

Neurobiol Aging. 2015 Dec;36(12):3187-3199. doi: 10.1016/j.neurobiolaging.2015.08.021. Epub 2015 Aug 31.

12.

Complement C3-Deficient Mice Fail to Display Age-Related Hippocampal Decline.

Shi Q, Colodner KJ, Matousek SB, Merry K, Hong S, Kenison JE, Frost JL, Le KX, Li S, Dodart JC, Caldarone BJ, Stevens B, Lemere CA.

J Neurosci. 2015 Sep 23;35(38):13029-42. doi: 10.1523/JNEUROSCI.1698-15.2015.

13.

Anti-Aβ antibodies incapable of reducing cerebral Aβ oligomers fail to attenuate spatial reference memory deficits in J20 mice.

Mably AJ, Liu W, Mc Donald JM, Dodart JC, Bard F, Lemere CA, O'Nuallain B, Walsh DM.

Neurobiol Dis. 2015 Oct;82:372-384. doi: 10.1016/j.nbd.2015.07.008. Epub 2015 Jul 26.

14.

Dissecting the Contribution of Vascular Alterations and Aging to Alzheimer's Disease.

Janota C, Lemere CA, Brito MA.

Mol Neurobiol. 2016 Aug;53(6):3793-3811. doi: 10.1007/s12035-015-9319-7. Epub 2015 Jul 5. Review.

PMID:
26143259
15.

The epigenetics of aging and neurodegeneration.

Lardenoije R, Iatrou A, Kenis G, Kompotis K, Steinbusch HW, Mastroeni D, Coleman P, Lemere CA, Hof PR, van den Hove DL, Rutten BP.

Prog Neurobiol. 2015 Aug;131:21-64. doi: 10.1016/j.pneurobio.2015.05.002. Epub 2015 Jun 11. Review.

PMID:
26072273
16.

Glio-vascular changes during ageing in wild-type and Alzheimer's disease-like APP/PS1 mice.

Janota CS, Brites D, Lemere CA, Brito MA.

Brain Res. 2015 Sep 16;1620:153-68. doi: 10.1016/j.brainres.2015.04.056. Epub 2015 May 9.

17.

Tau immunization: a cautionary tale?

Mably AJ, Kanmert D, Mc Donald JM, Liu W, Caldarone BJ, Lemere CA, O'Nuallain B, Kosik KS, Walsh DM.

Neurobiol Aging. 2015 Mar;36(3):1316-32. doi: 10.1016/j.neurobiolaging.2014.11.022. Epub 2014 Dec 30.

PMID:
25619661
18.

Exosomes neutralize synaptic-plasticity-disrupting activity of Aβ assemblies in vivo.

An K, Klyubin I, Kim Y, Jung JH, Mably AJ, O'Dowd ST, Lynch T, Kanmert D, Lemere CA, Finan GM, Park JW, Kim TW, Walsh DM, Rowan MJ, Kim JH.

Mol Brain. 2013 Nov 13;6:47. doi: 10.1186/1756-6606-6-47.

19.

Immunotherapy for Alzheimer's disease: hoops and hurdles.

Lemere CA.

Mol Neurodegener. 2013 Oct 22;8:36. doi: 10.1186/1750-1326-8-36. Review.

20.

Pyroglutamate-3 amyloid-β deposition in the brains of humans, non-human primates, canines, and Alzheimer disease-like transgenic mouse models.

Frost JL, Le KX, Cynis H, Ekpo E, Kleinschmidt M, Palmour RM, Ervin FR, Snigdha S, Cotman CW, Saido TC, Vassar RJ, St George-Hyslop P, Ikezu T, Schilling S, Demuth HU, Lemere CA.

Am J Pathol. 2013 Aug;183(2):369-81. doi: 10.1016/j.ajpath.2013.05.005. Epub 2013 Jun 7.

21.

MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice.

Liu B, Frost JL, Sun J, Fu H, Grimes S, Blackburn P, Lemere CA.

J Neurosci. 2013 Apr 17;33(16):7027-37. doi: 10.1523/JNEUROSCI.5924-12.2013.

22.

De-repression of FOXO3a death axis by microRNA-132 and -212 causes neuronal apoptosis in Alzheimer's disease.

Wong HK, Veremeyko T, Patel N, Lemere CA, Walsh DM, Esau C, Vanderburg C, Krichevsky AM.

Hum Mol Genet. 2013 Aug 1;22(15):3077-92. doi: 10.1093/hmg/ddt164. Epub 2013 Apr 11.

PMID:
23585551
23.

Galactic cosmic radiation leads to cognitive impairment and increased aβ plaque accumulation in a mouse model of Alzheimer's disease.

Cherry JD, Liu B, Frost JL, Lemere CA, Williams JP, Olschowka JA, O'Banion MK.

PLoS One. 2012;7(12):e53275. doi: 10.1371/journal.pone.0053275. Epub 2012 Dec 31.

24.

Complement component C3 and complement receptor type 3 contribute to the phagocytosis and clearance of fibrillar Aβ by microglia.

Fu H, Liu B, Frost JL, Hong S, Jin M, Ostaszewski B, Shankar GM, Costantino IM, Carroll MC, Mayadas TN, Lemere CA.

Glia. 2012 May;60(6):993-1003. doi: 10.1002/glia.22331. Epub 2012 Mar 21.

25.

A coding variant in CR1 interacts with APOE-ε4 to influence cognitive decline.

Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D, Sabuncu MR; Alzheimer's Disease Neuroimaging Initiative, Allen AN, Corneveaux JJ, Hardy JA, Huentelman MJ, Lemere CA, Myers AJ, Nicholson-Weller A, Reiman EM, Evans DA, Bennett DA, De Jager PL.

Hum Mol Genet. 2012 May 15;21(10):2377-88. doi: 10.1093/hmg/dds054. Epub 2012 Feb 17.

26.

Passive immunization against pyroglutamate-3 amyloid-β reduces plaque burden in Alzheimer-like transgenic mice: a pilot study.

Frost JL, Liu B, Kleinschmidt M, Schilling S, Demuth HU, Lemere CA.

Neurodegener Dis. 2012;10(1-4):265-70. doi: 10.1159/000335913. Epub 2012 Feb 16.

27.

Dietary supplementation with S-adenosyl methionine delayed amyloid-β and tau pathology in 3xTg-AD mice.

Lee S, Lemere CA, Frost JL, Shea TB.

J Alzheimers Dis. 2012;28(2):423-31. doi: 10.3233/JAD-2011-111025.

PMID:
22045486
28.

Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease.

Bateman RJ, Aisen PS, De Strooper B, Fox NC, Lemere CA, Ringman JM, Salloway S, Sperling RA, Windisch M, Xiong C.

Alzheimers Res Ther. 2011 Jan 6;3(1):1. doi: 10.1186/alzrt59.

29.

L-3-n-butylphthalide improves cognitive impairment and reduces amyloid-beta in a transgenic model of Alzheimer's disease.

Peng Y, Sun J, Hon S, Nylander AN, Xia W, Feng Y, Wang X, Lemere CA.

J Neurosci. 2010 Jun 16;30(24):8180-9. doi: 10.1523/JNEUROSCI.0340-10.2010.

30.

Amyloid-beta immunotherapy for Alzheimer's disease.

Fu HJ, Liu B, Frost JL, Lemere CA.

CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. Review.

31.

Can Alzheimer disease be prevented by amyloid-beta immunotherapy?

Lemere CA, Masliah E.

Nat Rev Neurol. 2010 Feb;6(2):108-19. doi: 10.1038/nrneurol.2009.219. Review. Erratum in: Nat Rev Neurol. 2010 Apr;6(4):183. Nat Rev Neurol. 2010 Jun;6(6):296.

32.

L-3-n-butylphthalide improves cognitive impairment induced by intracerebroventricular infusion of amyloid-beta peptide in rats.

Peng Y, Xing C, Xu S, Lemere CA, Chen G, Liu B, Wang L, Feng Y, Wang X.

Eur J Pharmacol. 2009 Oct 25;621(1-3):38-45. doi: 10.1016/j.ejphar.2009.08.036. Epub 2009 Sep 6.

PMID:
19737553
33.

Developing novel immunogens for a safe and effective Alzheimer's disease vaccine.

Lemere CA.

Prog Brain Res. 2009;175:83-93. doi: 10.1016/S0079-6123(09)17506-4. Review.

34.

Biochemical and immunohistochemical analysis of an Alzheimer's disease mouse model reveals the presence of multiple cerebral Abeta assembly forms throughout life.

Shankar GM, Leissring MA, Adame A, Sun X, Spooner E, Masliah E, Selkoe DJ, Lemere CA, Walsh DM.

Neurobiol Dis. 2009 Nov;36(2):293-302. doi: 10.1016/j.nbd.2009.07.021. Epub 2009 Aug 4.

35.

Neuroprotective natural antibodies to assemblies of amyloidogenic peptides decrease with normal aging and advancing Alzheimer's disease.

Britschgi M, Olin CE, Johns HT, Takeda-Uchimura Y, LeMieux MC, Rufibach K, Rajadas J, Zhang H, Tomooka B, Robinson WH, Clark CM, Fagan AM, Galasko DR, Holtzman DM, Jutel M, Kaye JA, Lemere CA, Leszek J, Li G, Peskind ER, Quinn JF, Yesavage JA, Ghiso JA, Wyss-Coray T.

Proc Natl Acad Sci U S A. 2009 Jul 21;106(29):12145-50. doi: 10.1073/pnas.0904866106. Epub 2009 Jul 6.

36.

Phosphorylation-dependent TDP-43 antibody detects intraneuronal dot-like structures showing morphological characters of granulovacuolar degeneration.

Kadokura A, Yamazaki T, Kakuda S, Makioka K, Lemere CA, Fujita Y, Takatama M, Okamoto K.

Neurosci Lett. 2009 Sep 29;463(1):87-92. doi: 10.1016/j.neulet.2009.06.024. Epub 2009 Jun 17.

PMID:
19539703
37.

Regional distribution of TDP-43 inclusions in Alzheimer disease (AD) brains: their relation to AD common pathology.

Kadokura A, Yamazaki T, Lemere CA, Takatama M, Okamoto K.

Neuropathology. 2009 Oct;29(5):566-73. doi: 10.1111/j.1440-1789.2009.01017.x. Epub 2009 Apr 21.

PMID:
19422539
38.

Increased DJ-1 expression under oxidative stress and in Alzheimer's disease brains.

Baulac S, Lu H, Strahle J, Yang T, Goldberg MS, Shen J, Schlossmacher MG, Lemere CA, Lu Q, Xia W.

Mol Neurodegener. 2009 Feb 25;4:12. doi: 10.1186/1750-1326-4-12.

39.

Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory.

Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE, Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan CM, Walsh DM, Sabatini BL, Selkoe DJ.

Nat Med. 2008 Aug;14(8):837-42. doi: 10.1038/nm1782. Epub 2008 Jun 22.

40.

Complement C3 deficiency leads to accelerated amyloid beta plaque deposition and neurodegeneration and modulation of the microglia/macrophage phenotype in amyloid precursor protein transgenic mice.

Maier M, Peng Y, Jiang L, Seabrook TJ, Carroll MC, Lemere CA.

J Neurosci. 2008 Jun 18;28(25):6333-41. doi: 10.1523/JNEUROSCI.0829-08.2008.

41.

Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization.

Klyubin I, Betts V, Welzel AT, Blennow K, Zetterberg H, Wallin A, Lemere CA, Cullen WK, Peng Y, Wisniewski T, Selkoe DJ, Anwyl R, Walsh DM, Rowan MJ.

J Neurosci. 2008 Apr 16;28(16):4231-7. doi: 10.1523/JNEUROSCI.5161-07.2008.

42.

Cerebral amyloid-beta protein accumulation with aging in cotton-top tamarins: a model of early Alzheimer's disease?

Lemere CA, Oh J, Stanish HA, Peng Y, Pepivani I, Fagan AM, Yamaguchi H, Westmoreland SV, Mansfield KG.

Rejuvenation Res. 2008 Apr;11(2):321-32. doi: 10.1089/rej.2008.0677.

PMID:
18341428
43.

l-3-n-Butylphthalide ameliorates beta-amyloid-induced neuronal toxicity in cultured neuronal cells.

Peng Y, Xing C, Lemere CA, Chen G, Wang L, Feng Y, Wang X.

Neurosci Lett. 2008 Mar 28;434(2):224-9. doi: 10.1016/j.neulet.2008.01.080. Epub 2008 Feb 14.

PMID:
18328624
44.
46.

Novel Abeta immunogens: is shorter better?

Lemere CA, Maier M, Peng Y, Jiang L, Seabrook TJ.

Curr Alzheimer Res. 2007 Sep;4(4):427-36. Review.

PMID:
17908047
47.

A beneficial role for IL-1 beta in Alzheimer disease?

Lemere CA.

J Clin Invest. 2007 Jun;117(6):1483-5.

48.

Developing novel immunogens for an effective, safe Alzheimer's disease vaccine.

Maier M, Seabrook TJ, Lemere CA.

Neurodegener Dis. 2005;2(5):267-72. Review.

PMID:
16909008
49.

Effects of huperzine A on amyloid precursor protein processing and beta-amyloid generation in human embryonic kidney 293 APP Swedish mutant cells.

Peng Y, Jiang L, Lee DY, Schachter SC, Ma Z, Lemere CA.

J Neurosci Res. 2006 Sep;84(4):903-11.

PMID:
16862548

Supplemental Content

Loading ...
Support Center